Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citrulline for BMT Toxicity Reduction
NCT00223730Phase 2Completed
- Sponsor
- Vanderbilt University
- Start
- Oct 2001
- Primary completion
- Dec 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic veno-occlusive disease (HVOD) and acute lung injury (ALI) comparing Citrulline with Placebo (2 arms). Primary endpoints: Incidence of Hepatic Veno-Occlusive Disease at 100 days and Incidence of Acute Lung Injury at 100 days. Started Oct 2001; status: completed.
02
Drugs
citrulline
03
Conditions
hepatic veno-occlusive disease (HVOD)acute lung injury (ALI)
Beyond the preview
Go deeper on NCT00223730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223730.